Cardiovascular risk in the 21st century: Identifying risk in primary prevention. Controlling risk in secondary prevention;Riesgo cardiovascular en el siglo XXI. Cómo detectarlo en prevención primaria. Cómo controlarlo en prevención secundaria

Revista Espanola de Cardiologia

Volumn 65, Issue SUPPL.2, 2012, Pages 3-9

  Mazón Ramos, Pilar ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

Risk factor Detection of subclinical disease Cardiovascular prevention

Indexed keywords

CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET; EXERCISE; HEART MUSCLE REVASCULARIZATION; HUMAN; LIFESTYLE MODIFICATION; REVIEW; SMOKING;

EID: 84865469653     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2012.07.004     Document Type: Article

References (35)

1. W. Kannel, T. Dawber, A. Kagan, N. Revotskie, and J. Stokes Factors of risk in the development of coronary heart disease-six-year follow-up experience Ann intern Med 55 1961 33 50
2. R. Conroy, K. Pyörälä, A. Fitzgerald, S. Sans, A. Menotti, and G. De Backer on behalf of the SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE Project Eur Heart J 24 2003 987 1003
3. P. Ridker, J. Buring, N. Rifai, and N. Cook Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score JAMA 297 2007 611 619
4. Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood institute; American Heart Association; World Heart Federation; international Atherosclerosis Society; and international Association for the Study of Obesity. Circulation. 2009; 120:1640-5.
5. G. Mancia, G. De Baker, A. Dominiczak, R. Cifkova, R. Fagard, and G. Germano Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007 Rev Esp Cardiol 60 2007 e1 e94
6. A. Go, G. Chertow, D. Fan, C. McCulloch, and C. Hsu Chronic kidney disease and the risk of death events and hospitalization N Engl J Med 351 2004 1296 1305
7. P. Ridker, J. MacFadyen, M. Cressman, and R. Glynn Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPiTER (Justification for the Use of Statins in Prevention-an intervention Trial Evaluating Rosuvastatin) trial J Am Coll Cardiol 55 2010 1266 1273
8. Z. Reiner, A. Catapano, G. De Backer, Graham i, R. Taskinen, and O. Wiklund ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Rev Esp Cardiol 64 1168. 2011 e1 e60
9. S. Sans, A. Fitzgerald, D. Royo, R. Conroy, and I. Graham Calibración de la tabla SCORE de riesgo cardiovascular para España Rev Esp Cardiol 60 2007 476 486
10. S. Yusuf, S. Hawken, S. Ounpuu, B. Dans, A. Avezum, and F. Lanas INTERHEART Study investigators, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the iNTERHEART study): case-control study Lancet 364 2004 937 952
11. J. Danesh, S. Erqou, M. Walker, S.G. Thompson, R. Tipping, and C. Ford Emerging Risk Factors Collaboration. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1. 1 million participants in 104 prospective studies of cardiovascular diseases Eur J Epidemiol 22 2007 839 869
12. R. Elosua, C. Carla Lluis, and G. Lucas Research into the genetic component of heart disease from linkage studies to genome-wide genotyping Rev Esp Cardiol 9 Supl B 2009 B24 B38
13. M. Naghavi Preventive cardiology: the SHAPE of the future. A synopsis from the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report Herz 5 2007 356 361
14. P. Greenland, J.S. Alpert, G.A. Beller, E.J. Benjamin, M.J. Budoff, and Z.A. Fayad 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 56 2010 e50 e103
15. A.H. Maas, Y.T. Van der Schouw, V. Regitz-Zagrosek, E. Swahn, Y.E. Appelman, and G. Pasterkamp Red alert for womenís heart: the urgent need for more research and knowledge on cardiovascular disease in women Eur Heart J 32 2011 1362 1817
16. B. Healy The Yentl syndrome N Engl J Med 325 1991 274 276
17. C.N. Bairey Merz The Yentl syndrome is alive and well Eur Heart J 32 2011 1313 1315
18. L. Mosca, E. Benjamin, K. Berra, J. Bezanson, R. Dolor, and D. Lloyd-Jones Effectiveness based guidelines for the prevention of cardiovascular disease in womenó2011 update: a guideline from the American Heart Association J Am Coll Cardiol 57 2011 1404 1423
19. V. Dzau, and E. Braunwald Resolved and unresolved issues in the prevention and treatment of coronary artery disease Am Heart J 121 1991 1244 1263
20. F. Alfonso, J. Segovia, M. Heras, and J. Bermejo [Cardiovascular prevention: always too late] Rev Esp Cardiol 61 2008 291 298
21. Smith S, Benjamin E, Bonow R, Braun L, Creager M, Franklin B, et al. World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458-73.
22. G.C. Fonarow, and A. Gawlinski Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles Am J Cardiol 85 2000 A10 A17
23. S. Yusuf Two decades of progress in preventing vascular disease Lancet 360 2002 2 3
24. S. Yusuf, S. islam, C.K. Chow, S. Rangarajan, G. Dagenais, and R. Diaz Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey, Prospective Urban Rural Epidemiology (PURE) Study investigators Lancet 378 2011 1231 1243
25. Garcia-Moll x, L. Fácila, P. Conthe, A. Zapata, R. Artigas, and V. Bertomeu investigadores del estudio CARACTER-BETA. [How beta-blockers are used in Spain?. Analysis of limitations in their use in internal medicine and cardiology: CARACTER-BETA study] Rev Esp Cardiol 64 2011 88 90
26. J. De Velasco, J. Cosín, J.L. López-Sendón, E. De Teresa, M. De Oya, and G. Sellers Nuevos datos sobre la prevención secundaria del infarto de miocardio en España, Resultados del estudio PREVESE II Rev Esp Cardiol 55 2002 801 809
27. J.R. González Juanatey, E. Alegría, J. Lozano, J.L. Llisterri, J.M. García-Acuña, and i. González- Maqueda impacto de la hipertensión en las cardiopatías en España, Estudio CARDiOTENS 1999 Rev Esp Cardiol 54 2001 139 149
28. A. Cordero, V. Bertomeu-Martínez, P. Mazón, L. Fácila, V. Bertomeu-González, and J. Cosín CARDiOTENS investigators, [Factors associated with uncontrolled hypertension in patients with and without cardiovascular disease] Rev Esp Cardiol 64 2011 587 593
29. J.R. González-Juanatey, A. Cordero, G.C. Vitale, B. González-Timón, P. Mazón, and V. Bertomeu [Magnitude and characteristics of residual lipid risk in patients with a history of coronary revascularization: the iCP-Bypass study] Rev Esp Cardiol 64 2011 862 868
30. M.F. Piepoli, U. Corr, W. Benzer, B. Bjarnason-Wehrens, P. Dendale, and D. Gaita Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation, Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation Eur J Cardiovasc Prev Rehabil 17 2010 1 17
31. J. Velasco, J. Cosín, J. Maroto, J. Muñiz, J. Casasnovas, Plaza i, and L. Tomás Guías de práctica clínica de la Sociedad Española de Cardiología en prevención cardiovascular y rehabilitación cardíaca Rev Esp Cardiol 53 2000 1095 1120
32. M. Latre, P. Mazón, E. Marcos, and E. García-Porrero Temas de actualidad en prevención cardiovascular y rehabilitación cardiaca Rev Esp Cardiol 62 Supl1 2009 4 13
33. D.A. Wood, K. Kotseva, S. Connolly, C. Jennings, A. Mead, and J. Jones EUROACTiON Study Group, Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTiON) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial Lancet 371 2008 1999 2012
34. A.M. Clark, L. Hartling, B. Vandermeer, S.L. Lissel, and F.A. McAlister Secondary prevention programmes for coronary heart disease: a meta-regression showing the merits of shorter, generalist, primary care-based interventions Eur J Cardiovasc Prev Rehabil 14 2007 538 546
35. D. Mozaffarian, P. Wilson, and W. Kannel Beyond established and novel risk factors lifestyle risk factors for cardiovascular disease Circulation 117 2008 3031 3038